2026-08-20T06:03:23Zhttps://docta.ucm.es/rest/oai/request

oai:docta.ucm.es:20.500.14352/933252025-03-18T14:05:11Zcom_20.500.14352_14col_20.500.14352_15

Glahn Martínez, Ana Bettina Jurado-Sánchez, Beatriz Benito Peña, María Elena Escarpa, Alberto Moreno Bondi, María Cruz 2024-01-16T11:22:20Z 2024-01-16T11:22:20Z 2024 Glahn-Martínez, Bettina, et al. «Magnetic Janus Micromotors for Fluorescence Biosensing of Tacrolimus in Oral Fluids». Biosensors and Bioelectronics, vol. 244, enero de 2024, p. 115796. https://doi.org/10.1016/j.bios.2023.115796. 0956-5663 10.1016/j.bios.2023.115796 https://hdl.handle.net/20.500.14352/93325 https://doi.org/10.1016/j.bios.2023.115796 https://www.sciencedirect.com/science/article/pii/S0956566323007388 Tacrolimus (FK506) is a macrolide lactone immunosuppressive drug that is commonly used in transplanted patients to avoid organ rejection. FK506 exhibits high inter- and intra-patient pharmacokinetic variability, making monitoring necessary for organ graft survival. This work describes the development of a novel bioassay for monitoring FK506. The bioassay is based on using polycaprolactone-based (PCL) magnetic Janus micromotors and a recombinant chimera receptor that incorporates the immunophilin tacrolimus binding protein 1A (FKBP1A) tagged with Emerald Green Fluorescent Protein (EmGFP). The approach relies on a fluorescence competitive bioassay between the drug and the micromotors decorated with a carboxylated FK506 toward the specific site of the fluorescent immunophilin. The proposed homogeneous assay could be performed in a single step without washing steps to separate the unbound receptor. The proposed approach fits the therapeutic requirements, showing a limit of detection of 0.8 ng/mL and a wide dynamic range of up to 90 ng/mL. Assay selectivity was evaluated by measuring the competitive inhibition curves with other immunosuppressive drugs usually co-administered with FK506. The magnetic propulsion mechanism allows for efficient operation in raw samples without damaging the biological binding receptor (FKBP1A-EmGFP). The enhanced target recognition and micromixing strategies hold considerable potential for FK506 monitoring in practical clinical use. eng http://creativecommons.org/licenses/by-nc-nd/4.0/ open access Attribution-NonCommercial-NoDerivatives 4.0 International Magnetic Janus micromotors for fluorescence biosensing of tacrolimus in oral fluids journal article